This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Things You Must Know Ahead of Philip Morris' (PM) Q1 Earnings
by Zacks Equity Research
Philip Morris' (PM) first-quarter 2020 performance is likely to reflect favorable pricing and gains from RRPs. However, soft cigarette volumes might have been a concern.
Coca-Cola (KO) to Report Q1 Earnings: What's in the cards?
by Zacks Equity Research
Coca-Cola's (KO) first-quarter 2020 results are expected to reflect the impacts of the coronavirus outbreak in China beginning January.
Coronavirus Ruins March Retail Sales: Top & Flop ETF Areas
by Sanghamitra Saha
March retail sales saw a record decline due to the coronavirus-led economic shutdown. These ETF areas won/lost in the month.
Clorox (CLX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Clorox (CLX) closed the most recent trading day at $195.75, moving +0.71% from the previous trading session.
Factors Setting Tone for Procter & Gamble's (PG) Q3 Earnings
by Zacks Equity Research
Procter & Gamble's (PG) third-quarter fiscal 2020 results are expected to reflect gains from continued operations of its facilities despite the coronavirus outbreak.
The Zacks Analyst Blog Highlights: Meritage Homes, Sarepta Therapeutics, The Clorox Company, The Hain Celestial Group and Entergy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Meritage Homes, Sarepta Therapeutics, The Clorox Company, The Hain Celestial Group and Entergy
The Zacks Analyst Blog Highlights: Bank of America, Citigroup, Koninklijke Philips, Zoom Video and The Clorox Company
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bank of America, Citigroup, Koninklijke Philips, Zoom Video and The Clorox Company
5 Stocks to Win Big This Brutal Q1 Earnings Season
by Tirthankar Chakraborty
There are certain sectors whose earnings are expected to perk up in the first quarter despite this pandemic. Such sectors include Construction, Medical, Consumer Staples and Utilities.
3 Highly-Ranked Stocks to Buy for the Coronavirus Economy & the Eventual Recovery
by Benjamin Rains
On today's episode of Full Court Finance, we explore three stocks that appear to be buys at the moment and down the road when the economy eventually turns around from the coronavirus downturn...
Trading a Record "Cannonball Run" Global Week Ahead
by John Blank
The choice for stock pickers looks bifurcated. Very short term? Play "the Cannonball Run" regime. That means buy defensive names, and/or steer clear of stocks altogether.
Clorox (CLX) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Clorox (CLX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Why Clorox (CLX) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Clorox (CLX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
5 Consumer Staple Stocks for Your Easter Basket Amid Coronavirus
by Vrishali Bagree
Amid coronavirus-led jitters, we have picked five consumer staple stocks with solid growth prospects. These stocks carry a favorable Zacks Rank and have gained at least 15% in a year.
Keurig Dr Pepper (KDP) Unveils Strategic Refinancing Program
by Zacks Equity Research
Keurig Dr Pepper (KDP) announces a strategic refinancing program with an aim to extend its debt maturities and enhance liquidity position.
Clorox (CLX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Clorox (CLX) closed at $181.51 in the latest trading session, marking a +0.07% move from the prior day.
Is The Clorox (CLX) Stock Outpacing Its Consumer Staples Peers This Year?
by Zacks Equity Research
Is (CLX) Outperforming Other Consumer Staples Stocks This Year?
5 Top Momentum Stocks for April Amid Coronavirus-Led Turmoil (Revised)
by Nalak Das
A handful of stocks have withstood the market mayhem in March, some of them are momentum players.
The Zacks Analyst Blog Highlights: Regeneron, Netflix, Clorox, NVIDIA and SBA
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron, Netflix, Clorox, NVIDIA and SBA
The Zacks Analyst Blog Highlights: Grocery Outlet, Sprouts Farmers, PLDT, Regeneron and Clorox
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Grocery Outlet, Sprouts Farmers, PLDT, Regeneron and Clorox
S&P Sees Worst-Ever Q1: 5 Stocks That Gained in the ETF
by Sweta Killa
Though all 11 sectors in the S&P 500 index were down in the quarter, information technology and healthcare fared better than others.
Forget S&P 500's Worst-Ever Q1: 5 Stocks Not to Fool You in Q2
by Sanghamitra Saha
While the novel coronavirus outbreak ravaged the equity world in Q1, investors can expect these five high potential S&P 500 members to gain in Q2.
6 Top S&P 500 Stocks That Have Surged Despite Worst-Ever Q1
by Nalak Das
The disappointing performance in Q1 is not due to any economic, financial or geopolitical factors but instead a health hazard ??? the coronavirus pandemic.
Top Ranked Momentum Stocks to Buy for April 1st
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, April 1st.
Why Clorox (CLX) Stock is a Long-Term Buy Far Beyond the Coronavirus
by Benjamin Rains
Clorox sells disinfectant products that kill germs at home and in healthcare settings, which makes it almost tailor-made for the coronavirus economy. Better still, Clorox's portfolio is far more diverse and CLX appears to be a solid longer-term buy...
5 Top Momentum Stocks for April Amid Coronavirus-Led Turmoil
by Nalak Das
A handful of stocks have withstood the market mayhem in March, some of them are momentum players.